PEB Concludes Commercial Agreement with Facey Medical Group

Company Announcement
31 March 2021



PEB CONCLUDES COMMERCIAL AGREEMENT WITH FACEY MEDICAL GROUP IN US

Cancer diagnostics company, Pacific Edge Limited (NZX: PEB) has concluded a commercial agreement with Facey Medical
Group, a physician owned medical group in California. The agreement covers the use of Cxbladder Detect and Cxbladder
Monitor for Facey Medical Group patients.

Facey Medical Group is a multi-specialty medical group with over 180 physicians providing care to more than 170,000
patients in the North & East regions of Los Angeles & Ventura Counties in California. This makes it similar in size to the
Mid-Central District Health Board in New Zealand. Facey Medical Group is also one of six California physician groups
affiliated with, or owned by Providence Health & Services, one of the largest health systems in the Western United States.

CEO of Pacific Edge, David Darling, said: “Physician owned organisations such as the Facey Medical Group are an
important customer group for Pacific Edge as we continue to expand the adoption and commercial use of Cxbladder in
the US. We were approached by the Group following a number of the urologists utilising our products and we are pleased
to move into a formal commercial relationship with them. Whilst test volumes are not expected to be large compared
to healthcare organisations such as Kaiser Permanente, this agreement demonstrates the ongoing commercial adoption
of Cxbladder in the US as we continue to position Cxbladder as the preferred diagnostic test for urologists evaluating
patients for bladder cancer.”

ENDS

For more information contact:

David Darling, Chief Executive Officer, Pacific Edge Ltd, T: +64 (3) 479 5800

For media assistance, please contact Jackie Ellis on T: +64 27 246 2505 or email jackie@ellisandco.co.nz

OVERVIEW www.pacificedge.co.nz www.pacificedgedx.com
Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer diagnostic company specialising in the discovery and
commercialisation of diagnostic and prognostic tests for better detection and management of cancer. Its Cxbladder suite of
non-invasive, simple to use and accurate diagnostic tests provide actionable results, and better detection and management of
urothelial cancer. The company is developing and commercialising its range of Cxbladder bladder cancer tests globally through
its wholly owned central laboratories in New Zealand and the USA. The company’s products have been tested and validated in
international multi-centre clinical studies.

ABOUT Cxbladder Triage www.cxbladder.com
Cxbladder Triage combines the power of the genomic biomarkers with additional phenotypic and clinical risk factors to
accurately identify patients with haematuria who have a low probability of bladder cancer and may not require a more
extensive urological evaluation. Cxbladder Triage is a tool for use by clinicians and physicians in primary evaluation of patients
with haematuria and is intended to reduce the need for an expensive and invasive work-up in patients who have a low
probability of having urothelial carcinoma.

ABOUT Cxbladder Detect www.cxbladder.com
Cxbladder Detect enables the non-invasive detection of bladder and other urinary tract cancers from a small volume of a
patients’ urine. Cxbladder Detect provides clinicians with a quick, cost effective and accurate measure of the presence of the
cancer as an effective adjunct to cystoscopy.

Company Announcement
31 March 2021


ABOUT Cxbladder Monitor www.cxbladder.com
Cxbladder Monitor allows urologists to monitor bladder cancer patients for recurrence of the disease. Bladder cancer has a
recurrence rate of 50-80% and requires life-long surveillance. Cxbladder Monitor accurately identifies patients with a prior
history of urothelial cancer (UC) whose Cxbladder Monitor score shows that they have a low probability of recurrent urothelial
carcinoma. Cxbladder Monitor is designed to be used as the preferred adjunct test to cystoscopy in the management of patients
for ongoing evaluation of recurrent bladder cancer.

ABOUT Cxbladder Resolve www.cxbladder.com
Cxbladder Resolve identifies those patients who are likely to have aggressive or more advanced bladder cancer. Cxbladder
Resolve, when used as part of the primary evaluation of haematuria and/or in conjunction with other Cxbladder tests (Triage,
Detect), is designed to assist clinicians by accurately identifying patients with a high probability of having high grade or late
stage bladder cancer, for whom alternative or expedited treatment options may be warranted, or who can be prioritised for
further investigation in high throughput settings.

Refer to www.cxbladder.com for more information.